A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Cutaneous/Subcutaneous Primary or Metastatic Tumors
Latest Information Update: 17 Feb 2025
At a glance
- Drugs Nitric oxide (Primary) ; Antineoplastics
- Indications Skin cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Beyond Air
Most Recent Events
- 10 Feb 2025 According to a Beyond Cancer media release, topline data from the Phase 1b portion of the study are anticipated late in calendar 2025 or early-2026.
- 03 Dec 2024 According to a Beyond Cancer media release, the company announced that topline data from the Phase 1b portion of the study are anticipated in the second half of 2025.
- 03 Dec 2024 Planned number of patients changed from 38 to 58.